Autopsy report · NCT00927290
Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance
Cause of deathRegulatory or ethics
“Suspension of use of medicine containing Pioglitazone by French regulatory agency”
Life of this trial
- Registered 5 months before it started.
- Ran for about 2 years 7 months before it stopped.
- 40 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Sponsor type
- Government (non-US federal)
- Conditions
- Chronic Hepatitis C; Insulin Resistance
- Interventions
- Pioglitazone; Placebo
- Participants
- 40
- Sites
- 1
- Countries
- France
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.